June 2022 EIPM Director’s Memo

June 2022 EIPM Director’s Memo

Dear Members of the Englander Institute,

I really enjoy talking to people about the exciting work happening at the EIPM, it can lead to all kinds of collaborations, professional opportunities, and new sources of support.

That’s one of the reasons I was happy to invite Charlie Roberts, co-founder and Chief Growth Officer of Freenome, to visit recently with our staff and tour our labs. Because VIPs & donors love these experiences so much we decided to create a new EIPM Lab Tour video, so an even wider audience can enjoy the same experience. I encourage everyone to watch, like, and share this video widely.

We have a number of exciting career opportunities we are hoping to fill soon, from Research Technician positions, to Front End Developers & Machine Learning Analysts, to a Clinical Research Fellowship in Precision Medicine. Thank you in advance for sharing these opportunities within your professional networks.

Thank you for your hard work and continued dedication to our mission.

Sincerely,

Olivier Elemento, Ph.D.

 

News Coverage & Awards
Congratulations to our Director for Liquid Biopsy Research, Dr. Pashtoon Kasi, for receiving funding for a new investigator initiated clinical trial he’s going to be developing for neoadjuvant therapy for patients with colon cancer involving immunotherapy.

EIPM Member Dr. Richard R. Furman was interviewed for the article, “Dr. Furman on Current Treatment Options in CLL,” by OncLive on May 10th.

EIPM Member Dr. Niro Anandasabapathy was interviewed for the article “T-Cell Behavior in Tumors Affects Immunotherapy Response, Predicts Patient Survival,” which appeared in Genetic Engineering and Biotechnology News on May 11th.

Dr. Melissa B. Davis was interviewed for the broadcast news story, “Racial and ethnic disparities in breast cancer outcomes,” that appeared on NY1 News on May 4th.

Events
Dr. Iman Hajirasouliha presented a Cornell Engineering Seminar, “Deep Learning Imaging — Applications in Pathology and Embryology,” on Friday, May 6th.

Dr. Melissa B. Davis participated in a National Breast Cancer Coalition panel discussion diving into healthcare disparities in the US and how activists can facilitate change in the movement toward health equity for all, May 1st.

Upcoming:

Publications
Our Clinical Director Dr. Cora N. Sternberg co-authored “Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials,” in Clinical Cancer Research on May 13th. Dr. Sternberg also recently published “Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021,” in European Urology on April 18th.

Dr. Niroshana Anandasabapathy was the lead author, along with co-author Dr. Akanksha Verma and myself, on the publication “An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes,” in Cancer Cell on May 9th.

Dr. Melissa B. Davis published, along with co-authors Drs. Brittany D. Lord and Rachel N. Martini, “Understanding how genetic ancestry may influence cancer development,” in a Science & Society Special Issue: Cancer Health Disparities in Trends in Cancer, in April 2022.

I was happy to co-author a new paper by WCM investigators Drs. Jedd D. Wolchok and Taha Merghoub, “Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions,” in the Journal of Experimental Medicine on May 23rd.

Dr. Pashtoon Kasi published the Commentary, “Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck,” in the May 2022 edition of The Oncologist.

Our colleague Dr. Ashley Doane and I collaborated on “Alterations in transcriptional networks in cancer: the role of noncoding somatic driver mutations,” in the August 2022 edition of Current Opinion in Genetics and Development.

Our former EIPM colleague Dr. Yariv Houvras published “Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer,” with EIPM co-authors Rohan Bareja, Kenneth Wha Eng, Princesca Dorsaint, Dr. David C. Wilkes, and myself; Pathology and Laboratory Medicine Department co-authors Drs. Shaham Beg, Theresa Scognamiglio, James Patrick Solomon, Wei Song; and Drs. Juan Miguel Mosquera and Andrea Sboner from the WCM Pathology and Laboratory Medicine Department, and the EIPM, in the Journal of Experimental Medicine on May 5th.

Congratulations to WCM Pathology and Laboratory Medicine’s Dr. Hussein Alnajar who published “Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab,” in Molecular Case Studies on May 26th with EIPM colleagues Hiranmayi Ravichandran, Dr. André Figueiredo Rendeiro, Jyothi Manohar, Noah Greco, Michael Sigouros, Dr. Bishoy Faltas, Cora N. Sternberg, and myself; along with joint WCM Pathology and Laboratory Medicine/EIPM colleagues Drs. Kentaro Ohara, Wael Al Zoughbi, and Juan Miguel Mosquera.

Nearly a dozen WCM investigators collaborated on the new paper “Weakly-supervised tumor purity prediction from frozen H&E stained slides,” in eBioMedicine by Dr. Iman Hajirasouliha, with EIPM co-authors Michael Sigouros, Alex Sigaras, Troy Kane, Dr. Pegah Khosravi, and myself, with Drs. Juan Miguel Mosqueraand Majd Al Assaad from the WCM Pathology and Laboratory Medicine department and the EIPM, June 2022.

A range of WCM researchers, led by EIPM Member Dr. Ekta Khurana, published “Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets,” in Science on May 27th, with EIPM co-authors Duo Xu, Alexander Martinez Fundichely, Kenneth Eng, Rohan Bareja, Clinical Director Dr. Cora N. Sternberg; Dr. Shaham Beg, whose primary affiliation is now WCM Pathology and Laboratory Medicine; and Dr. Andrea Sboner from the WCM Pathology and Laboratory Medicine department and our Director of Informatics and Computational Biology.

Dr. Marcin Imieliński from the WCM Pathology & Laboratory Medicine department, also affiliated with the NY Genome Center, Meyer Cancer Center, and the EIPM, published “Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing,” in Nature Biotechnology on May 30th with a range of Pathology and Laboratory Medicine and EIPM co-authors, including EIPM Drs. Sarah Kudman, David Wilkes, Christopher E. Barbieri; and Dr. Juan Miguel Mosquera, affiliated with WCM Pathology and Laboratory Medicine and is our Director of Research Pathology.

# # #